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ABSTRACT 
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly 
used medications in the world. NSAID-induced adverse reactions involve upper gastrointestinal 
(GI) tract complications, which can be life-threatening. Objectives: The study was conducted to 
explore the current prescription pattern of non-steroidal anti-inflammatory drugs (NSAIDs) and the 
prevalence of NSAID-induced gastrointestinal(GI) risk factors of orthopedic adult 
inpatient.Materials and methods:  A prospective observational NSAIDs induced GI risk related 
study was conducted over a period of 6 months by clinical pharmacist. Study cohort included 105 
orthopaedic inpatients who are taking or will be taking NSAIDs for more than a week. A self-
administered questionnaire was completed by each patient. A simplified risk scoring scale (the 
Standardized Calculator of Risk for Events; SCORE) was used to measure patients‟ risk for GI 
complications. The pattern of NSAIDs prescription was identified from medical 
recordings.Results: The study groups were stratified into four risk groups according to GI SCORE 
tool, 27.6% of the patients belonged to high risk or very high risk groups for GI complications. 
Analysis of prescription pattern revealed that 11.4% of the patients aged over 65 yr, 19% with co 
morbid disease were prescribed with COX-2 selective inhibitor. 
Conclusion: In this study assessment of prescription pattern and GI risk factors for NSAIDs were 
evaluated and in conclusion, physician‟s considerate prescription of NSAIDs with well-
understanding of each patient‟s GI risk factors is strongly encouraged to prevent serious GI 
complications
Introduction 
Although there are many definitions of an ADR, an 
internationally accepted description is that of the World 
Health Organization (WHO): „„A response to a drug that is 
noxious and unintended, and that occurs at doses normally 
used in humans for the prophylaxis, diagnosis, or therapy of 
disease or for the modification of physiological function”. The 
NSAIDs are a group of chemically dissimilar agents that differ 
in their antipyretic, analgesic, and anti-inflammatory activities. 
GI complications occur in 1%-5% of patients taking NSAIDs 
for more than one year and result in high costs and mortality. 
Rates of GI complications may vary substantially depending 
on each patient‟s clinical characteristics. Identification of the 
NSAID-related GI risk factors is therefore crucial in 
determining the proper treatment for each patient. Many 
studies already reported that the development of serious GI 
complications are highly correlated with certain factors, 
including health status of disability, increasing age, 
concomitant use of systemic steroids or anticoagulants, history 
of a GI ulcer of bleed, diagnosis of rheumatoid arthritis, 
certain patterns of prior NSAID use, history of cardiovascular 
disease, smoking status, and NSAID-related GI symptoms .  
 Prior to market release of the first cyclooxygenase-2 
enzyme(COX-2) selective inhibitor (celecoxib), northern 
California health maintenance organization (HMO) developed 
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a treatment guideline for the use of NSAIDs based on the 
Standardized Calculator of Risk for Events (SCORE) program 
developed at Stanford University, Division of Immunology 
and Rheumatology. The SCORE tool stratifies patients by risk 
of developing serious GI complications using patient 
characteristics that have assigned points. It is desirable that 
physicians consider each patient‟s clinical factors before 
prescribing NSAIDs. In this study, we evaluated the current 
prescription pattern of NSAIDs and the prevalence of NSAID-
induced GI risk factors of orthopaedic patients. 
 
Materials and methods 
 
The study was conducted in a multispecialty tertiary care 
hospital, in the department of orthopedics. A total of 105 
patients were enrolled in the study. The study was designed to 
be a prospective observational study, carried out in single 
center for a period of 6 months. The sample population was 
selected by inclusion–exclusion criteria. Adult in-patients of 
orthopedic department who have used or will be using 
NSAIDs for more than a week were included  Patients with 
difficulty in answering questionnaire and  patients who are 
unwilling to participate in the study are excluded from the 
study.The protocol of the study was submitted to Institutional 
Human Ethics Committee (IHEC) of hospital. The protocol 
was approved by the committee with the approval number 
SJPCEC/P25/PP/2014/034 and the hospital approval number 
SJCP/DIR/A.20/2015-2016. 
The study was conducted by collecting the data from the 
patient‟s medical records from orthopedics department. GI 
Standardized Calculation of Risk Estimation was done through 
case sheets and patient interview. A specially designed data 
entry form which includes GI SCORE (GI Standardised 
Calculation of Risk Estimation) calculator to asses GI risk. 
The GI SCORE was made and validated by Dr.Prof. G. Singh 
Department of Immunology and Rheumatology, Stanford 
university California. The tool was used after obtaining 
permission from its creators. 
 
 
 
Results  
This prospective observational study on “Prescription pattern 
of NSAIDs and the prevalence of gastrointestinal risk in 
orthopaedics patients” has assessed the prescribing pattern of 
NSAIDs for orthopaedic problems and the occurrence of GI 
risk events in the same patients. A total of 105 patients who 
were admitted in the orthopaedic department were enrolled in 
the study, in which Women accounted for 81.9% of the 
patients [Table 1] and the average age for the group was 
54.32(21-95) yrs. When dividing into two age subgroups 
37(23.8%) patients were aged over 65 years[Table 2]. Arthritis 
was the most common indication for NSAIDs (45.7%) 
followed by spinal diseases (18.1%) and fracture 
(14.2%).[Table 4]Among the GI risk factors identified, the 
presence of co morbid diseases( cardiovascular, renal, hepatic 
diseases, diabetes mellitus, hypertension etc) [55.2%] was the 
most prevalent risk factor in the overall study population, 
followed by current poor health status (34.28%), old age (≥65 
yrs) [23.8%] ,history of steroid use (14.2%), history of GI 
symptom (13.3%),heavy drinking habit (13.3%),anticoagulant 
use (12.3%),  SSRI use (10.4%),aspirin use (8.5%),  heavy 
smoking habit (8.5%),long term NSAID use(3.8%), 
rheumatoid arthritis(1.9%), previous hospitalization history 
due to GI events(1%). [Table no.3].When the study groups 
were stratified into four risk groups according to GI SCORE 
tool,38.1% belongs to low risk,34.3%  of the patients belonged 
to  moderate risk  8.6 % of the patients were in very high risk 
and 19% are in  high risk groups for GI complications [Table 
7].  When the type of prescription was analyzed in overall 
study groups, Lornoxicam was the most commonly used 
NSAID, comprising 51.4% of the patients. Etoricoxib 
(32.3%), Diclofenac (14.2%), Aceclofenac( 11.4%), 
Piroxicam (3.8%), Ibuprofen ( 2.8%), Aspirin (2%) were 
followed consecutively. [Table 5].Analysis of prescription 
pattern revealed that only 19% of patients with  co morbid 
diseases( cardiovascular, renal, hepatic diseases, diabetes 
mellitus, hypertension etc)  , 11.4% of patients aged over 65 
yrs , 7.6% of patients with current poor health status ,6.6% of 
patients with concomitant  anticoagulant use, 3.8 % of patients 
with  history of GI symptom, 2 % of patients using SSRIs , 1 
% of patients with heavy smoking and drinking habit to 
decrease the risk of GI complications by prescribing selective 
COX-2 inhibitors.[Table 6].Analysis of the measures taken to 
reduce the GI risk shows 89% of patients were prescribed with  
proton pump inhibitor and the rest 11% were on H2 receptor 
antagonist [Table 8] 
 
 
Distribution Based On Gender 
 
Table 1: Distribution of the sample population based on gender 
 
 
 
Study population Frequency (N=105) Percentage (%) 
Male 19 18.10 
Female 86 81.90 
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Fig 1: Percentage distribution based on gender 
The figure shows the percentage distribution of the study population based on gender 
Distribution of the sample population based on age: 
Table2: Distribution based on age 
Age No. of patient  Percentage of patient 
<20 0  0 
20-29 9  8.57 
30-39 8  7.61 
40-49 24  22.85 
50-59 25  23.8 
60-69 26  24.76 
70-79 9  8.57 
80-89 3  2.85 
90-99 1  0.95 
 
 
Fig 2: Percentage distribution based on age 
The figure depicts the percentage distribution of the study population based on age . 
Age 
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Distribution based on gastrointestinal risk factors 
Table 3: Gastrointestinal (GI) risk factors in the overall study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3: Percentage distribution of gastrointestinal risk factors 
The figure shows the percentage distribution of the Gastrointestinal(GI) risk factors in the overall study population 
 
                                    GI risk factors Percent of cases (%) 
Need for long-term NSAID use 3.8 
Age over 65 yr 23.8 
Comorbid disease (cardiovascular, renal, liver, 
diabetes,hypertension) 
55.2 
History of GI symptom 13.3 
Aspirin use 8.5 
Heavy smoking habit 8.5 
Heavy drinking habit 13.3 
History of steroid use 14.2 
Currently poor health status 34.28 
Rheumatoid arthritis 1.9 
Previous hospitalization history due to GI events 1 
Selective serotonin reuptake inhibitor (SSRI) use 10.4 
Anticoagulant use 12.3 
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Distribution based on the diagnosis at the time of hospital visit 
Table 4: List of diagnosis at the time of hospital visit 
 
 
Diagnosis 
 
Total Gender Age (yr) 
Male(n = 19) Female(n = 86) < 65(n = 80) ≥ 65(n = 25) 
Arthritis 45.7% 6 42 38 10 
Knee arthritis 26.6% 1 29 21 9 
Periarthritis 9.5% 3 7 10  
Rheumatoid 
arthritis 
1.9%  2 2  
Spinal disease 18.1% 3 16 15 4 
Spondylosis 3.8% 1 3 3 1 
Fracture 14.2% 8 7 12 3 
Wrist/hand fracture 4.7% 4 1 4 1 
Foot/ankle fracture 6.6% 1 6 6 1 
Femur fracture 1.9% 1 1 2  
Other diseases 21.9% 2 21 15 8 
 
 
Fig 4: Distribution based on diagnosis 
The figure depicts the diagnosis at the time of hospital visit 
Distribution based on the prescription pattern of NSAIDs 
Table 5:  The type of prescription in overall study population 
 
 
 
 
 
 
Drugs Total Male Female <65 >65 
Lornoxicam 51.4 5.7 45.7 37.1 14.2 
Aceclofenac 11.4 2 6.6 8.5 2.8 
Diclofenac 14.2 2 12.3 11.4 2.8 
Etoricoxib 32.3 4.7 27.6 25.7 6.6 
Aspirin 2 1 1 - 2 
Ibuprofen 2.8 - 2.8 2 1 
Piroxicam 3.8 - 3.8 3.8 - 
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Fig 5: Percentage distribution of prescription patterns of NSAIDs 
The  figure depicts the prescription pattern of NSAIDs 
Distribution based on Prescription pattern of COX-2 inhibitor according to the GI risk factors 
Table 6: Prescription pattern of COX-2 inhibitor according to the GI risk factors 
GI risk factors Selective COX-2 inhibitor use(units in 
%) 
Age 
<65yr >65yr 
Anticoagulant use 6.6 6 1 
Age over 65yrs 11.4 0 12 
Selective serotonin reuptake 
inhibitors(SSRI) use 
2 1 1 
Co morbid disease 19 16 4 
Currently poor health status 7.6 5 3 
History of GI symptom 3.8 2 2 
Heavy smoking habit 1 0 1 
Heavy drinking habit 1 0 1 
 
 
Fig 6: Distribution based on prescription patterns of COX-2 inhibitor according to GI risk factors 
GI risk factors 
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The figure depicts the prescription patterns on COX-2 inhibitors based on GI risk factors 
Distribution of sample population based on GI score 
Table 7: Distribution of sample population based on GI score 
Risk level Level 1 
(<10 points) 
Level 2 
(11-15) 
Level3 
(16-20) 
Level 4 
(>20 points) 
NO: of patients (%) 38.1 34.3 19.0 8.6 
 
 
Fig 7: Percentage distribution of sample population based on GI score 
This figure shows the percentage distribution of the study population based on the GI score 
Distribution based on drugs prescribed to reduce NSAID induced GI risk 
Table 8: Distribution of sample population based on drugs used to prevent NSAID induced GI risk 
 
 
 
 
Fig 8: Percentage distribution of sample population based on drugs used to prevent NSAID induced GI risk 
Drugs Percentage of patients(%) 
Proton pumP inhibitor 89 
H2 receptor antagonist 11 
GI risk factors 
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This figure shows the percentage distribution of the study population based on the drugs used  to prevent NSAID induced GI risk 
Discussion  
All the individuals participated in the study (105) were 
grouped according to their gender for analysis as Table 1 & 
Figure 1.The majority of the people of the study population 
were female, i.e. about 81.9% remaining 18.1% was male 
populations. 
The respondents were grouped according to their age into 
9categories for analyzing as table 2 and figure 2.The majority 
of patients belongs to category 60-69 i.e.26 (24.76%) with a 
mean age of 64.About 20-29 patients were belongs to category 
9(8.57%),30-39 patients belongs to category 8(7.61%),40-49 
belongs to category 24(22.85%),50-59 belongs to category 25 
(23.8%),70-79 belongs to category 9( 8.57%),80-89 belongs to 
category 3 (2.85%),90-99 (0.95%) (Table 2 &Figure 5). This 
study revealed that co morbid disease was the most prevalent 
risk factor in orthopaedic patients, which is followed by 
currently poor health(34.28%) ,age over 65 yrs(23.8%),history 
of steroid use(14.2%),history of GI symptoms(13.3%), 
anticoagulant use(12.3%) and SSRI use(10.4%) (table 3 & 
figure 3) .a similar study conducted shows long term NSAID 
use is the most prevalent risk factor   From table 4 & figure 4 , 
Arthritis was the most common cause of taking NSAIDs 
(45.7% ), followed by other diseases (21.9%),spinal disease 
(18.1%) and fracture (14.2%).When the type of prescription 
was analyzed in overall study groups, Lornoxicam (51.4%) 
was the most commonly used NSAIDs. Etoricoxib (COX-2 
selective inhibitor)(32.3%), Diclofenac(14.2%) ,Aceclofenac 
(11.4%)  were followed consecutively  in table 5 and figure 5.
 
                         Analysis of prescription pattern revealed that 
only 6.6% of patients with concomitant anticoagulant use, 
11.4% of the patients aged over 65 yr, 19% with comorbid 
disease were prescribed COX-2 selective inhibitor to decrease 
the risk of developing GI complications (table 6 and figure 6). 
In table 7 and figure 7, the study groups were stratified into 
four risk groups according to GI SCORE tool, 38.1% belongs 
to low risk,34.3%  of the patients belonged to  moderate risk, 
19% belongs to high risk and 8.6% belongs to very high 
risk.In table 8 and figure 8 ,the study groups were stratified 
based on drugs prescribed to reduce NSAID induced GI 
risk.89% of patients were prescribed with  proton pump 
inhibitor and the rest 11% were on H2 receptor antagonist. 
 
 
Conclusion 
During the study period, most of the risk factors which caused 
NSAID induced GI problems were analyzed and the 
prescription pattern of both selective and non-selective COX 
inhibitors is analyzed. According to the GI SCORE tool 27.6% 
of patients falls in high risk or very high risk category, the use 
of selective COX -2 inhibitors are strongly encouraged. A 
well-understanding of each patient‟s GI risk factors is 
necessary in order to maximize cost effectiveness and to 
prevent serious GI complications. 
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